Prostate Cancer Treatment Decisions Reviewed
One of the largest studies of its kind concludes that most
older men with early prostate cancer do not shorten their survival odds if
they adopt a "wait-and-see" approach to the disease.
In fact, most such patients will die of other causes or
they simply will not develop any complications from the cancer, says a
report presented at the 2008 Genitourinary Cancers
Symposium.
"Many elderly men with lower risk cancer may do well with
conservative management," concludes study author Grace Lu-Yau, at the Cancer
Institute of New Jersey.
"Each patient facing a treatment decision has to ask
himself what is the potential survival benefit of various treatments and the
potential side effects of various treatments," says Lu-Yau.
She says patients should then compare this potential risk
of side effects with the potential risk of cancer complications if the
cancer is left untreated - and ask themselves which treatment option is
their personal preference.
The question of whether to treat or not treat prostate
cancer has long absorbed experts.
Although one in six men in the US will be diagnosed with
prostate cancer in their lifetime, many of the malignancies are
slow-growing, and there is currently no reliable way to identify which men
will benefit from treatment.
Better knowledge of the natural history of the disease
(i.e., what happens without any treatment) would help guide treatment
decisions, explains Lu-Yau.
This study is one of the first to look at the natural
history of prostate cancer since PSA (prostate-specific antigen) blood
testing has become commonplace. PSA tests can detect a prostate cancer six
to 13 years earlier than previous methods.
Lu-Yau and her colleagues looked at data on more than
9,000 men with Stage I or II prostate cancer diagnosed between 1992 and 2002
who did not undergo treatment. The mean age of participants was 77 years.
Seventy-two percent of these men died of other causes or
didn't have enough cancer progression to warrant surgery or radiation, the
researchers found. For the remaining 2,675 men who did receive treatment,
the median time between diagnosis and start of therapy was more than 10
years.
Not surprisingly, men with less aggressive disease
survived longer than those with more aggressive tumors.
"For elderly men with localized prostate cancer, the
potential survival benefit for treatment is most likely modest, therefore it
is very critical to weigh the risk of having side effects of various
treatments with the risk of developing cancer-related complications down the
road," says Lu-Yau.
"The majority of patients will die of other causes or
remain alive without significant major complications," she says.
A second study presented at the conference found that
giving salvage radiation therapy (SRT) to men whose PSA levels rise after
having their prostate removed can reduce their risk of dying from the cancer
by more than 60 percent.
SRT is typically given only after a recurrence, not after
an initial diagnosis of prostate cancer, notes study lead author Dr. Bruce
Trock, at Johns Hopkins University School of Medicine.
Existing studies have either not been large enough or long
enough in duration to determine if SRT prolongs survival.
In this retrospective analysis of 635 men who had
experienced a recurrence after having their prostate removed, 62 percent of
those who did not receive any salvage therapy were still alive after 10
years, versus 86 percent of those who received SRT and 82 percent of those
who received SRT plus hormone therapy.
Men whose PSA doubling time (the amount of time it took
for PSA levels to double from when in first becomes detectable) was six
months or less had the greatest benefit.
"If another study was able to replicate our data, it could
lead to clinical trial that would eventually support a way to determine who
should get immediate adjuvant radiation and who could wait until the time of
recurrence to have SRT," Dr. Trock says.
"The question is, could a benefit be achieved in some of
these men if you waited to see whether they recurred or not?" he asks.
Always consult your physician for more information.